Valuation: United Therapeutics Corporation

Market Cap 23.03B 20.2B 18.62B 17.43B 32.68B 2,173B 33.36B 224B 86.58B 1,074B 86.49B 84.6B 3,724B P/E 2026 *
19.9x
P/E 2027 * 17.2x
Enterprise Value 19.67B 17.24B 15.89B 14.88B 27.9B 1,855B 28.48B 191B 73.92B 917B 73.85B 72.24B 3,179B EV / Sales 2026 *
6.03x
EV / Sales 2027 * 4.99x
Free-Float
53.71%
Yield 2026 *
-
Yield 2027 * -
1 day-0.13%
1 week+1.13%
Current month-2.54%
1 month-4.92%
3 months+3.79%
6 months+7.00%
Current year+11.37%
1 week 533.49
Extreme 533.49
555.32
1 month 532.59
Extreme 532.59
563.04
Current year 455.63
Extreme 455.63
609.35
1 year 272.12
Extreme 272.12
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 1996-06-25
President 54 2016-06-25
Director of Finance/CFO 58 2015-03-12
Director TitleAgeSince
Director/Board Member 78 2001-12-31
Chairman 71 1996-06-25
Director/Board Member 92 2001-12-31
Date Insider Type Main position Quantity % Market Cap.
06-23Fiscal year

Chief Executive Officer

28,500 0.0671%
06-22Fiscal year

Chief Executive Officer

28,500 0.0671%
06-21Fiscal year

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%+1.13%+90.90%+152.26% 23.03B
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.38%+7.31%+36.98%+64.32% 363.91B
Weighted average by Cap. +3.82%+8.88%+42.07%+80.62%

Financials

2026 *2027 *
Net sales 3.26B 2.86B 2.64B 2.47B 4.63B 308B 4.73B 31.71B 12.27B 152B 12.26B 11.99B 528B 3.7B 3.24B 2.99B 2.8B 5.25B 349B 5.36B 35.94B 13.91B 172B 13.89B 13.59B 598B
Net income 1.27B 1.12B 1.03B 963M 1.81B 120B 1.84B 12.36B 4.78B 59.33B 4.78B 4.67B 206B 1.48B 1.3B 1.2B 1.12B 2.1B 140B 2.15B 14.39B 5.57B 69.06B 5.56B 5.44B 239B
Net Debt -3.37B -2.95B -2.72B -2.55B -4.78B -318B -4.88B -32.71B -12.66B -157B -12.64B -12.37B -544B -4.59B -4.02B -3.71B -3.47B -6.51B -433B -6.64B -44.54B -17.24B -214B -17.22B -16.84B -741B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Employees
1,400
Date Price Change Volume
26-06-26 US$542.66 -0.13% 1,022,244
26-06-25 US$543.39 -1.18% 285,355
26-06-24 US$549.90 +1.02% 377,592
26-06-23 US$544.33 +1.12% 1,081,315
26-06-22 US$538.30 +0.32% 620,875
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
542.66USD
Average target price
665.23USD
Spread / Average Target
+22.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock